The number of foreign investors participating in Catalan biotech companies has gone from 0 to 50, and over the past five years alone, the figure has increased tenfold, according to the latest Biocat report.
Catalonia’s biotech sector has continued to boom despite the political storms that struck the region and the rest of Spain just over a year ago and foreign and domestic investment is on the rise.
Biocat, the agency that coordinates and promotes the health care and life sciences sector in Catalonia, has recently published a...
With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.
Restructuring Edition: Karyopharm is reducing its workforce by 20% as it seeks alternatives to extend its cash runway, but Pacira’s production improvements created efficiency that necessitate an 8% layoff in manufacturing. Jasper, Century, Sage, Leap and Prothena also cut jobs.
Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.
The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.
The Austrian firm is delisting from the NASDAQ and closing down.
Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.
Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.
